Topics

Glioblastoma | Treatment | Immunotherapy | Nivolumab

Home > Publications > Topics > Glioblastoma > Treatment > Immunotherapy > Nivolumab

*Hendriksen JD, Locallo A, Maarup S, Debnath O, Ishaque N, Hasselbach B, Skjøth-Rasmussen J, Yde CW, Poulsen HS, Lassen U, Weischenfeldt J.
Immunotherapy drives mesenchymal tumour cell state shift and TME immune response in glioblastoma patients.
Neuro Oncol. 2024 May 2:noae085. doi: 10.1093/neuonc/noae085. PMID: 38695342. Observational study˰ ˍ

Alan O, Bulbul MC, Enlice MA, Mandel NM.
Immunotherapy-related secondary hemophagocytosis in a glioblastoma patient: response to cytokine-directed therapy.
Immunotherapy. 2025 Jan 15:1-7. doi: 10.1080/1750743X.2025.2451604. PMID: 39812468. Case report˰ ˍ

Neuro-Oncology Clinical Research Program; Camphausen K.
Phase II Trial Evaluating the Association of Peripheral Blood Immunologic Response to Therapeutic Response After Adjuvant Treatment with Immune Checkpoint Inhibition (ICI) in Patients with Newly Diagnosed Glioblastoma or Gliosarcoma.
medRxiv [Preprint]. 2025 Dec 30:2025.12.23.25342908. doi: 10.64898/2025.12.23.25342908. PMID: 41607658. Trial registration ID: NCT04817254. ˍ